Croda receives boost as leading US investment bank turns positive

Croda International PLC's shares recently slumped 10% following its latest results, despite the chemicals group matching half-year expectations and maintaining full-year guidance. However, Morgan Stanley has upgraded the stock to “overweight,” asserting that the market is overly pessimistic. The bank highlights Croda's robust 45% profit margins, achievable future earnings forecasts, and a current valuation trading below its long-term average, suggesting the downturn presents a buying opportunity for patient investors.

Analysis

Croda International PLC (LSE:CRDA) presents a stark divergence between recent market sentiment and its operational fundamentals. Despite a 10% share price slump following its latest results, the company met half-year expectations and maintained its full-year guidance, a sign of stability in a volatile sector. The market's negative reaction was driven by concerns over ongoing price pressures and regulatory uncertainty in its US pharma division. However, Morgan Stanley’s upgrade to “overweight” posits that this pessimism is excessive. The bank's analysis suggests that price cuts are largely a pass-through of lower raw material costs rather than a signal of deteriorating pricing power. Furthermore, Croda maintains robust profit margins of 45%, which are noted as being among the best in the industry. With shares now trading below their long-term average valuation, the current price may not fully reflect the company's achievable earnings forecasts and the potential for future growth from its investments.

Key Decisions for Investors

• Investors could view the recent share price weakness as a potential buying opportunity, given the stock is trading below its long-term average valuation and has received a significant analyst upgrade.
• It is important to assess the company's ability to maintain its industry-leading 45% profit margins, as this is a key pillar of the bullish thesis and counters concerns about price pressures.
• Monitor for any developments regarding the regulatory uncertainty in the US pharma division, as a resolution could act as a significant catalyst for the stock, validating the view that near-term market concerns were overstated.